Leadership Overview
Cadila Pharmaceuticals has 10 executives leading key functions including operations, finance, revenue, human resources, public affairs, and regulatory affairs.
Driven by integrated operations, Cadila Pharmaceuticals is dedicated to advancing healthcare through comprehensive manufacturing of APIs, finished formulations, biotechnology products, and more, impacting global markets.
Driven by integrated operations, Cadila Pharmaceuticals is dedicated to advancing healthcare through comprehensive manufacturing of APIs, finished formulations, biotechnology products, and more, impacting global markets.
Leadership Roles at Cadila Pharmaceuticals
Sandeep Rathi - Chief Financial Officer
Sandeep Rathi, the Chief Financial Officer at Cadila Pharmaceuticals, manages the company's financial strategy and operations. Rathi oversees all fiscal activities, including budgeting, financial planning, and investment analysis, ensuring robust financial health. This critical role involves safeguarding company assets and optimizing financial performance across all integrated business units, from API manufacturing to OTC food supplements. The Chief Financial Officer plays a pivotal part in securing funding for research and development initiatives and managing investor relations. By providing strategic financial guidance, Sandeep Rathi supports Cadila Pharmaceuticals' long-term growth objectives and its expansion into new markets. Rathi's expertise ensures compliance with financial regulations and drives profitability, reinforcing the company's stable market position.
Vijayesh Gupta - Chief Operating Officer
Vijayesh Gupta, the Chief Operating Officer at Cadila Pharmaceuticals, directs the company's extensive manufacturing operations. Overseeing the production of APIs, intermediates, and finished formulations, Gupta ensures seamless integration across the entire product lifecycle. This leadership role involves optimizing production efficiency and maintaining stringent quality control standards for all pharmaceutical machinery and biotechnology products. Gupta's strategic oversight guarantees that Cadila Pharmaceuticals consistently delivers high-quality products to meet global demand. The Chief Operating Officer drives operational excellence, focusing on scalable manufacturing processes that support the company's integrated business model. By managing complex supply chains and production schedules, Vijayesh Gupta directly contributes to the company's market presence and its ability to innovate within the pharmaceutical sector.
Mitul Dave - Chief Operating Officer- CSBU
Mitul Dave, the Chief Operating Officer- CSBU at Cadila Pharmaceuticals, spearheads operations within the Consumer Self-Care Business Unit. Dave focuses on enhancing the production and distribution of over-the-counter (OTC) products and food supplements, ensuring market availability and consumer satisfaction. This role involves optimizing the supply chain for consumer-facing goods and driving innovation in product development for this specific segment. The Chief Operating Officer- CSBU collaborates with marketing and sales teams to expand market reach for OTC offerings. By streamlining operations within the CSBU, Mitul Dave ensures that Cadila Pharmaceuticals effectively serves the consumer health market. Dave's leadership drives efficiency and growth in the self-care product portfolio, reinforcing the company's diverse manufacturing capabilities.
Prabodh Joshi - Group President, Human Resources & Corporate Communications
Prabodh Joshi, the Group President, Human Resources & Corporate Communications at Cadila Pharmaceuticals, leads talent management and organizational development. Joshi oversees all HR functions, including recruitment, employee relations, and compensation, ensuring a skilled and motivated workforce. This role is crucial for fostering a positive corporate culture and managing internal communications effectively across the company's integrated operations. The Group President, Human Resources & Corporate Communications also directs external communications strategies, enhancing Cadila Pharmaceuticals' brand reputation and public image. By developing robust HR policies and executing strategic communication plans, Prabodh Joshi supports the company's growth and operational stability. Joshi's efforts cultivate employee engagement and strengthen corporate identity.
Raj Vyas - Group President, Corporate & Public Affairs
Raj Vyas, the Group President, Corporate & Public Affairs at Cadila Pharmaceuticals, manages the company's external relations and stakeholder engagement. Vyas oversees government liaison, regulatory advocacy, and corporate social responsibility initiatives, ensuring alignment with business objectives. This position is vital for navigating the complex regulatory landscape and building strong relationships with public entities and industry associations. The Group President, Corporate & Public Affairs champions Cadila Pharmaceuticals' commitment to ethical practices and community development. By fostering positive public perception and advocating for favorable policies, Raj Vyas significantly contributes to the company's operational environment and long-term sustainability. Vyas's strategic engagement strengthens the company's societal impact.
Suresh Balasubramanian - President - Plantations
Suresh Balasubramanian, the President - Plantations at Cadila Pharmaceuticals, directs operations related to the company's plantation interests. Balasubramanian oversees the management and development of plantation resources, ensuring sustainable practices and optimal yield. This role involves managing agricultural processes and supply chains that may support specific product lines or raw material sourcing for the company. The President - Plantations focuses on maximizing the efficiency and productivity of plantation assets. By ensuring the effective management of these agricultural operations, Suresh Balasubramanian contributes to Cadila Pharmaceuticals' diversified business portfolio and its commitment to integrated resource management. Balasubramanian's leadership ensures the viability of plantation-based operations.
Wilton Franca - President - Latam
Wilton Franca, the President - Latam at Cadila Pharmaceuticals, leads the company's strategic initiatives and operations across the Latin American region. Franca is responsible for expanding market presence, driving sales, and ensuring regulatory compliance within the Latam markets. This role involves developing tailored strategies to meet the specific needs of consumers and healthcare providers in South America. The President - Latam collaborates with regional teams to optimize distribution networks and enhance product accessibility. By spearheading growth in this key geographic area, Wilton Franca significantly contributes to Cadila Pharmaceuticals' global expansion efforts. Franca's leadership strengthens the company's position in emerging markets.
Arani Chatterjee - President
Arani Chatterjee, the President at Cadila Pharmaceuticals, provides overarching leadership and strategic direction for key business segments. Chatterjee oversees critical functions, ensuring alignment with the company's mission to deliver high-quality pharmaceutical products. This role involves driving operational excellence and fostering innovation across various departments, including manufacturing, research, and development. The President works closely with other senior executives to achieve corporate objectives and enhance market competitiveness. By guiding strategic initiatives and promoting a culture of continuous improvement, Arani Chatterjee plays a vital part in Cadila Pharmaceuticals' sustained growth and success. Chatterjee's leadership ensures cohesive execution of company strategy.
Sanjay Shrivastava - Global President, Regulatory Affairs
Sanjay Shrivastava, the Global President, Regulatory Affairs at Cadila Pharmaceuticals, directs the company's compliance and regulatory strategy worldwide. Shrivastava ensures that all products meet stringent international standards and regulatory requirements across diverse markets. This critical role involves managing submissions for product approvals, maintaining compliance with evolving regulations, and mitigating regulatory risks. The Global President, Regulatory Affairs collaborates closely with R&D, manufacturing, and commercial teams to facilitate market access for new and existing products. By upholding the highest standards of regulatory compliance, Sanjay Shrivastava safeguards Cadila Pharmaceuticals' reputation and market integrity. Shrivastava's expertise is essential for global product launches and sustained market presence.
Ranvir Rana - Head Chief Revenue Officer, Business Development
Ranvir Rana, the Head Chief Revenue Officer, Business Development at Cadila Pharmaceuticals, drives revenue generation and strategic growth initiatives. Rana oversees all sales operations and identifies new business opportunities, expanding the company's market footprint. This leadership position involves forging key partnerships and developing strategies to increase revenue streams across all product categories, including APIs, formulations, and biotechnology products. The Head Chief Revenue Officer, Business Development works closely with R&D and manufacturing to align commercial strategies with product development pipelines. By cultivating new ventures and optimizing existing revenue channels, Ranvir Rana significantly contributes to Cadila Pharmaceuticals' market expansion and financial success. Rana's focus is on sustainable revenue growth and market penetration.
Explore Leadership Teams in Manufacturing
ANI Pharmaceuticals, Inc. is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities.
Company Leadership NL
SS
MP
SC
Founded in 1993 and located in Cambridge, Massachusetts, Takeda Oncology is the oncology specialty business unit of Takeda Pharmaceutical. Takeda Oncology develops and produces oncology therapies for patients around the world.
Company Leadership CB
RS
Parabolic Drugs Limited is a vertically integrated, research-based pharmaceutical manufacturer and exporter, specializing in the production of over 50 active pharmaceutical ingredients (APIs) and intermediates across various therapeutic segments. The company operates four large-scale facilities, including three state-of-the-art manufacturing plants and a custom synthesis and R&D center. With a focus on backward and forward integration, world-class infrastructure, and strong R&D capabilities, Parabolic Drugs is committed to delivering high-quality products. Their diverse product portfolio is supported by intellectual property rights, including Drug Master Files (DMFs) and patents for novel processes.
Company Leadership AN
AJ
VG
YB
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Company Leadership TI
CS
SP
MD
Frequently Asked Questions Regarding Cadila Pharmaceuticals Top Executives and Leadership Team
